Michael Mussallem compensation by year
Edwards Lifesciences Summary Compensation Table · all 8 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Salary | $976,731 | $995,385 | $1,034,769 | $1,072,240 | $1,121,299 | $1,153,040 | $1,213,038 | $604,321 |
| Bonus | — | — | — | $0 | $0 | $0 | — | — |
| Stock awards | $2,943,863 | $3,391,586 | $3,409,941 | $3,641,664 | $3,731,409 | $5,230,175 | $5,583,038 | $399,972 |
| Option awards | $3,409,180 | $3,631,053 | $3,958,800 | $4,235,402 | $4,232,880 | $5,501,118 | $6,186,115 | — |
| Non-equity incentive | $2,228,226 | $2,597,000 | $1,668,227 | $2,381,117 | $734,993 | $1,581,770 | $869,400 | $602,640 |
| Pension and deferred compensation | — | — | — | $0 | $0 | $0 | — | — |
| All other | $176,099 | $183,294 | $207,212 | $190,550 | $230,352 | $147,202 | $140,554 | $198,804 |
| Total | $9,734,099 | $10,798,318 | $10,278,949 | $11,520,973 | $10,050,933 | $13,613,305 | $13,992,145 | $1,805,737 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Edwards Lifesciences Corp DEF 14A filed March 26, 2024, accession 0001099800-24-000032, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Edwards Lifesciences Corp filed document, accession 0001099800-24-000032. Every figure is read from that document and cited to the page and table it appears in. Filed March 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 17,866 | $1,362,283 | — |
| PSU | 8,850 | $674,813 | — |
| RSU | 4,485 | $341,981 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Edwards Lifesciences Corp's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Edwards Lifesciences’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Bernard Zovighian | Chief Executive Officer | $12,869,020 |
| Scott Ullem | Corporate Vice President, Chief Financial Officer | $5,949,153 |
| Larry Wood | Corporate Vice President | $5,395,034 |
| Catherine Szyman | Corporate Vice President, Critical Care | $4,340,031 |
| Donald Bobo | Corporate Vice President, Strategy & Corporate Development | $4,291,799 |
| Michael Mussallem · this page | Former Chief Executive Officer and Chairman of the Board (1) | $1,805,737 |
Board service
Edwards Lifesciences board · FY2021–FY2022How this board is paid
Company policy: Edwards Lifesciences pays directors a $80,000 cash retainer and $250,000 in RSUs. As stated in Edwards Lifesciences's FY2022 proxy.
The full Edwards Lifesciences compensation record
free company briefThis page is one person within Edwards Lifesciences's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Edwards Lifesciences proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Edwards Lifesciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.